Business Context and Reporting Period
This Form 8-K Current Report was filed by CareDx, Inc. on March 2, 2015. The filing reports a corporate governance event regarding the appointment of a new director and committee member.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of William A. Hagstrom to the Board of Directors and the Audit Committee, effective March 2, 2015. Mr. Hagstrom will serve as a Class II Director with a term expiring at the 2017 annual meeting.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The document details Mr. Hagstrom's background, including his role as CEO of Octave Bioscience Inc. and former President of Crescendo Bioscience, Inc. It also outlines his compensation, which includes an option to purchase 10,948 shares of common stock vesting over three years, subject to continued service.
Important Facts for Investors to Verify
- William A. Hagstrom's appointment to the Board and Audit Committee is effective immediately as of March 2, 2015.
- Mr. Hagstrom received an option grant for 10,948 shares of CareDx common stock.
- The option grant vests in equal monthly installments over a three-year period.
- Mr. Hagstrom's term as a Class II Director expires at the 2017 annual meeting of stockholders.